Comorbidity in disease-free survivors of cervical cancer compared with the general female population

Oncology

Volumn 74, Issue 3-4, 2008, Pages 207-215

  Shin, Dong Wook ^a   Nam, Joo Hyun ^b   Kwon, Yong Chul ^a   Park, Sang Yoon ^a   Bae, Duk Soo ^c   Park, Chong Taik ^e   Cho, Chi Heum ^f   Lee, Jong Min ^d   Park, Sang Min ^a   Yun, Young Ho ^a  

^a National Cancer Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Kyung Hee University College of Medicine   (South Korea)

^e CHA University   (South Korea)

^f Keimyung University School of Medicine   (South Korea)

Author keywords

Cervical cancer; Comorbidity; Disease free survivor; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL DISEASE; HEALTH SURVEY; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SEXUAL DYSFUNCTION; TERTIARY HEALTH CARE; UTERINE CERVIX CANCER; WOMEN'S HEALTH;

CASE-CONTROL STUDIES; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; SICKNESS IMPACT PROFILE; SURVIVORS; UTERINE CERVICAL NEOPLASMS;

EID: 49549107750     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151368     Document Type: Article

References (47)

1. Houterman S, Janssen-Heijnen ML, Hendrikx AJ, van den Berg HA, Coebergh JW: Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study. Crit Rev Oncol Hematol 2006;58:60-67.
2. Janssen-Heijnen ML, Maas HA, Houterman S, Lemmens VE, Rutten HJ, Coebergh JW: Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer 2007;43:2179-2193.
3. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
4. Ogle KS, Swanson GM, Woods N, Azzouz F: Cancer and comorbidity: redefining chronic diseases. Cancer 2000;88:653-663.
5. Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML: Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst 2004;96:1322-1330.
6. Peipert JF, Wells CK, Schwartz PE, Feinstein AR: The impact of symptoms and comorbidity on prognosis in stage Ib cervical cancer. Am J Obstet Gynecol 1993;169:598-604.
7. Park SY, Bae DS, Nam JH, Park CT, Cho CH, Lee JM, Lee MK, Kim SH, Park SM, Yun YH: Quality of life and sexual problems in disease-free survivors of cervical cancer compared with the general population. Cancer 2007;110:2716-2725.
8. Levy PS, Lemeshow S: Sampling of Populations: Methods and Applications. New York, Wiley, 1991.
9. Fayers P, Aaronson N, Bjordal K: The EORTC QLQ-C30 Scoring Manual, ed 3. Brussels, European Organization for Research and Treatment of Cancer, 2001.
10. Yun YH, Park YS, Lee ES, Bang SM, Heo DS, Park SY, You CH, West K: Validation of the Korean version of the EORTC QLQ-C30. Qual Life Res 2004;13:863-868.
11. Greimel ER, Kuljanic Vlasic K, Waldenstrom AC, Duric VM, Jensen PT, Singer S, Chie W, Nordin A, Bjelic Radisic V, Wydra D: The European Organization for Research and Treatment of Cancer (EORTC) Qualityof-Life questionnaire cervical cancer module: EORTC QLQ-CX24. Cancer 2006;107:1812-1822.
12. Rubin DB: On principles for modeling propensity scores in medical research. Pharmacoepidemiol Drug Saf 2004;13:855-857.
13. Jenkins P, Earle-Richardson G, Burdick P, May J: Handling nonresponse in surveys: analytic corrections compared with converting nonresponders. Am J Epidemiol 2008;167:369-374.
14. Cochran WG: The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics 1968;24:295-313.
15. D'Agostino RB Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
16. Sloan JA, Dueck A: Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J Biopharm Stat 2004;14:73-96.
17. Hobday TJ, Kugler JW, Mahoney MR, Sargent DJ, Sloan JA, Fitch TR, Krook JE, O'Connell MJ, Mailliard JA, Tirona MT, Tschetter LK, Cobau CD, Goldberg RM: Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol 2002;20:4574-4580.
18. Sloan JA: Assessing the clinical significance of quality of life (QOL) measures. SoCRA SOURCE, 2003, pp 23-25, http://www.socra.org/pdf/ 200311_AssessingClinSigQual-OfLife.pdf.
19. Yancik R, Havlik RJ, Wesley MN, Ries L, Long S, Rossi WK, Edwards BK: Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol 1996;6:399-412.
20. Seltzer V: Smoking as a risk factor in the health of women. Int J Gynaecol Obstet 2003;82:393-397.
21. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT: Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265-279.
22. Sagstuen H, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM: Blood pressure and body mass index in longterm survivors of testicular cancer. J Clin Oncol 2005;23:4980-4990.
23. Oh JH, Baum DD, Pham S, Cox M, Nguyen ST, Ensor J, Chen I: Long-term complications of platinum-based chemotherapy in testicular cancer survivors. Med Oncol 2007;24:175-181.
24. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, de Vries EG, Willemse PB, Mulder NH, van den Berg MP, Koops HS, Sleijfer DT: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725-1732.
25. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513-1523.
26. Kim DS: Chemotherapy for cervical cancer. J Korean Med Assoc 1992;35:317-321.
27. Siu SS, Cheung TH, Chan PK, Lin CK, Lo KW: Patients with malignant or pre-malignant cervical lesion have increased risk of becoming hepatitis B carrier. J Exp Clin Cancer Res 2007;26:77-81.
28. Strasser SI, Sullivan KM, Myerson D, Spurgeon CL, Storer B, Schoch HG, Murakami CS, McDonald GB: Cirrhosis of the liver in long-term marrow transplant survivors. Blood 1999;93:3259-3266.
29. Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ: Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol 2005;23:6596-6606.
30. Hale GA, Marina NM, Jones-Wallace D, Greenwald CA, Jenkins JJ, Rao BN, Luo X, Hudson MM: Late effects of treatment for germ cell tumors during childhood and adolescence. J Pediatr Hematol Oncol 1999;21:115-122.
31. Baker KS, Gurney JG, Ness KK, Bhatia R, Forman SJ, Francisco L, McGlave PB, Robison LL, Snyder DS, Weisdorf DJ, Bhatia S: Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the bone marrow transplant survivor study. Blood 2004;104:1898-1906.
32. Toomey DP, Cahill RA, Geraghty J, Thirion P: Radiation enteropathy. Ir Med J 2006;99:215-217.
33. van Dam JH, Gosselink MJ, Drogendijk AC, Hop WC, Schouten WR: Changes in bowel function after hysterectomy. Dis Colon Rectum 1997;40:1342-1347.
34. Ohta H, Masuzawa T, Ikeda T, Suda Y, Makita K, Nozawa S: Which is more osteoporosis-inducing, menopause or oophorectomy? Bone Miner 1992;19:273-285.
35. Boogerd W, ten Bokkel Huinink WW, Dalesio O, Hoppenbrouwers WJ, van der Sande JJ: Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol 1990;9:255-263.
36. Kumar M, Kedar A, Neiberger RE: Kidney function in long-term pediatric survivors of acute lymphoblastic leukemia following allogeneic bone marrow transplantation. Pediatr Hematol Oncol 1996;13:375-379.
37. Fossa SD, Aass N, Winderen M, Bormer OP, Olsen DR: Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 2002;13:222-228.
38. Firat S, Murray K, Erickson B: High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes. Int J Radiat Oncol Biol Phys 2003;57:201-207.
39. Arredondo SA, Elkin EP, Marr PL, Latini DM, DuChane J, Litwin MS, Carroll PR: Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: Data from CaPSURE. Urology 2006;67:559-565.
40. Bae JM, Kim S, Kim YW, Ryu KW, Lee JH, Noh JH, Sohn TS, Hong SK, Park SM, You CH, Kim JH, Lee MK, Yun YH: Health-related quality of life among disease-free stomach cancer survivors in Korea. Qual Life Res 2006;15:1587-1596.
41. Bush TL, Miller SR, Golden AL, Hale WE: Self-report and medical record report agreement of selected medical conditions in the elderly. Am J Publ Health 1989;79:1554-1556.
42. Klabunde CN, Reeve BB, Harlan LC, Davis WW, Potosky AL: Do patients consistently report comorbid conditions over time? Results from the prostate cancer outcomes study. Med Care 2005;43:391-400.
43. Klabunde CN, Harlan LC, Warren JL: Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care 2006;44:921-928.
44. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D: A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007;17:584-590.
45. Mitra N, Schnabel FR, Neugut AI, Heitjan DF: Estimating the effect of an intensive surveillance program on stage of breast carcinoma at diagnosis: a propensity score analysis. Cancer 2001;91:1709-1715.
46. Honda K, Goodwin RD: Cancer and mental disorders in a national community sample: findings from the national comorbidity survey. Psychother Psychosom 2004;73:235-242.
47. Oeffinger KC, McCabe MS: Models for delivering survivorship care. J Clin Oncol 2006;24:5117-5124.